<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662919</url>
  </required_header>
  <id_info>
    <org_study_id>FRA-FLX-17-11226</org_study_id>
    <secondary_id>2017-A03220-53</secondary_id>
    <nct_id>NCT03662919</nct_id>
  </id_info>
  <brief_title>One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study</brief_title>
  <acronym>PERFUSE</acronym>
  <official_title>PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to describe the one-year persistence in participants treated by Flixabi (infliximab)&#xD;
      or Imraldi (Adalimumab) as prescribed by the physician for each of the 5 following&#xD;
      indications: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis&#xD;
      (PsA), Crohn's Disease (CD) [adults and children] and Ulcerative Colitis (UC) [adults for&#xD;
      both treatments and children only for Flixabi].&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who are Still Treated with Either Flixabi or Imraldi at 12 Months</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants, either infliximab naïve or switched from Remicade or CT-P13 to Flixabi, who are still treated with Flixabi, and either adalimumab naïve or switched from Humira or other adalimumab biosimilars to Imraldi, who are still treated with Imraldi, at 12 months for RA, AS, PsA, CD (adults and children), and UC (adults for both treatments and children only for Flixabi) will be reported.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2274</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Spondylitis, Ankylosing</condition>
  <condition>Arthritis, Psoriatic</condition>
  <condition>Crohn's Disease</condition>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Flixabi</arm_group_label>
    <description>Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imraldi</arm_group_label>
    <description>Adalimumab naive participants or participants who were previously treated with other adalimumab biosimilars will receive Imraldi (adalimumab) as prescribed by physician according to the local prescribing procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Flixabi</arm_group_label>
    <other_name>Flixabi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Imraldi</arm_group_label>
    <other_name>Imraldi</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants either infliximab naïve or switched from Remicade or CT-P13 to Flixabi who are&#xD;
        treated with Flixabi, and either adalimumab naïve or switched from Humira or other&#xD;
        adalimumab biosimilars to Imraldi who are treated with Imraldi, for RA, AS, PsA, CD, and UC&#xD;
        as prescribed by the physician in clinical practice.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion/ Exclusion Criteria&#xD;
&#xD;
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Adult participant (18 years and over)&#xD;
&#xD;
               -  treated for one of the following conditions: RA, AS, PsA, CD, UC.&#xD;
&#xD;
               -  either active substance naïve or treated with the originator or another&#xD;
                  biosimilar at baseline.&#xD;
&#xD;
               -  for whom the treating physician has decided to treat by (naïve) or switch from&#xD;
                  originator or another biosimilar to Flixabi or Imraldi.&#xD;
&#xD;
               -  participants who had initiated Flixabi or Imraldi at most 12 months before the&#xD;
                  baseline will also be included in the cohort.&#xD;
&#xD;
          -  Paediatric participants (6-17 years):&#xD;
&#xD;
               -  treated for one of the following conditions: CD, UC.&#xD;
&#xD;
               -  either active substance naïve or treated with another biosimilar at baseline.&#xD;
&#xD;
               -  for whom the treating physician has decided to treat by (naïve) or switch to&#xD;
                  Flixabi (for both indications) or Imraldi (only for Crohn's disease).&#xD;
&#xD;
               -  participants who had initiated Flixabi or Imraldi at most 12 months before the&#xD;
                  baseline will also be included in the cohort.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participant treated for psoriasis.&#xD;
&#xD;
          -  Participant who are not to be followed up in the same investigator site for 2 years&#xD;
             after baseline.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caluire et Cuire</city>
        <state>Auvergne-Rhône-Alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne-Rhône-Alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne-Rhône-Alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne-Rhône-Alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Pierre-Bénite</city>
        <state>Auvergne-Rhône-Alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pierre-Bénite</city>
        <state>Auvergne-Rhône-Alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Etienne</city>
        <state>Auvergne-Rhône-Alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne-Franche-Comté</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Brest</city>
        <state>Bretagne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest</city>
        <state>Bretagne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chambray les Tours</city>
        <state>Centre-Val De Loire</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orléans</city>
        <state>Centre-Val De Loire</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reims</city>
        <state>Grand Est</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <state>Grand Est</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <state>Grand Est</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens</city>
        <state>Hauts-de-France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de-France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de-France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Bobigny</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bobigny</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clichy</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colombes</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Créteil</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 4</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 5</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 6</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouen</city>
        <state>Normandie</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayonne</city>
        <state>Nouvelle-Aquitaine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle-Aquitaine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>La Rochelle</city>
        <state>Nouvelle-Aquitaine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Rochelle</city>
        <state>Nouvelle-Aquitaine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Limoges</city>
        <state>Nouvelle-Aquitaine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Nîmes</city>
        <state>Occitanie</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nîmes</city>
        <state>Occitanie</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Toulouse</city>
        <state>Occitanie</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <state>Occitanie</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Angers</city>
        <state>Pays De La Loire</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cannes</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Crau</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulon</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

